Institution
Stanford University
Education•Stanford, California, United States•
About: Stanford University is a education organization based out in Stanford, California, United States. It is known for research contribution in the topics: Population & Transplantation. The organization has 125751 authors who have published 320347 publications receiving 21892059 citations. The organization is also known as: Leland Stanford Junior University & University of Stanford.
Topics: Population, Transplantation, Medicine, Cancer, Gene
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Combinatorial interactions and stoichiometric ratios between the type I and II receptors may determine the extent of TGF-beta binding and the resulting biological activities.
Abstract: Transforming growth factor-beta (TGF-beta) affects cellular proliferation, differentiation, and interaction with the extracellular matrix primarily through interaction with the type I and type II TGF-beta receptors. The type II receptors for TGF-beta and activin contain putative serine-threonine kinase domains. A murine serine-threonine kinase receptor, Tsk 7L, was cloned that shared a conserved extracellular domain with the type II TGF-beta receptor. Overexpression of Tsk 7L alone did not increase cell surface binding of TGF-beta, but coexpression with the type II TGF-beta receptor caused TGF-beta to bind to Tsk 7L, which had the size of the type I TGF-beta receptor. Overexpression of Tsk 7L inhibited binding of TGF-beta to the type II receptor in a dominant negative fashion. Combinatorial interactions and stoichiometric ratios between the type I and II receptors may therefore determine the extent of TGF-beta binding and the resulting biological activities.
399 citations
••
TL;DR: In this paper, a finite-volume formulation is presented that solves the three-dimensional, non-hydrostatic Navier-Stokes equations with the Boussinesq approximation on an unstructured, staggered, z-level grid.
399 citations
••
Cleveland Clinic1, Stanford University2, University of Florida3, Rush University Medical Center4, University of Illinois at Chicago5, Royal North Shore Hospital6, University Medical Center Groningen7, Lenox Hill Hospital8, James Cook University Hospital9, Sahlgrenska University Hospital10, University of Oklahoma Health Sciences Center11, Case Western Reserve University12, Bryn Mawr Hospital13, Christiana Care Health System14, University of Düsseldorf15, Danbury Hospital16, University of Saskatchewan17, Duke University18, Karolinska University Hospital19, College of the Holy Cross20, University of California, San Francisco21, University of California, Los Angeles22, Wake Forest Baptist Medical Center23, University Hospital of Wales24, Johns Hopkins University School of Medicine25, Indiana University26
TL;DR: The Neuromodulation Appropriateness Consensus Committee (NACC) of the International Neurodulation Society evaluated evidence regarding the safety and efficacy of neurostimulation to treat chronic pain, chronic critical limb ischemia, and refractory angina and recommended appropriate clinical applications.
Abstract: Introduction: The Neuromodulation Appropriateness Consensus Committee (NACC) of the International Neuromodulation Society (INS) evaluated evidence regarding the safety and efficacy of neurostimulation to treat chronic pain, chronic critical limb ischemia, and refractory angina and recommended appropriate clinical applications. Methods: The NACC used literature reviews, expert opinion, clinical experience, and individual research. Authors consulted the Practice Parameters for the Use of Spinal Cord Stimulation in the Treatment of Neuropathic Pain (2006), systematic reviews (1984 to 2013), and prospective and randomized controlled trials (2005 to 2013) identified through PubMed, EMBASE, and Google Scholar. Results: Neurostimulation is relatively safe because of its minimally invasive and reversible characteristics. Comparison with medical management is difficult, as patients considered for neurostimulation have failed conservative management. Unlike alternative therapies, neurostimulation is not associated with medication-related side effects and has enduring effect. Device-related complications are not uncommon; however, the incidence is becoming less frequent as technology progresses and surgical skills improve. Randomized controlled studies support the efficacy of spinal cord stimulation in treating failed back surgery syndrome and complex regional pain syndrome. Similar studies of neurostimulation for peripheral neuropathic pain, postamputation pain, postherpetic neuralgia, and other causes of nerve injury are needed. International guidelines recommend spinal cord stimulation to treat refractory angina; other indications, such as congestive heart failure, are being investigated. Conclusions: Appropriate neurostimulation is safe and effective in some chronic pain conditions. Technological refinements and clinical evidence will continue to expand its use. The NACC seeks to facilitate the efficacy and safety of neurostimulation.
399 citations
••
TL;DR: This work directly measures the effects of aging in human tissue by performing single-cell transcriptome analysis of 2,544 human pancreas cells from eight donors spanning six decades of life and discovers a novel mutational signature in healthy aging endocrine cells.
399 citations
••
TL;DR: Deceleration in the decline of all CVD, HD, and stroke mortality rates has occurred since 2011, and strategic goals for lowering the burden of CVD set by the American Heart Association and the Million Hearts Initiative may not be reached.
Abstract: Importance Heart disease (HD) and cancer are the 2 leading causes of death in the United States. During the first decade of the 21st century, HD mortality declined at a much greater rate than cancer mortality and it appeared that cancer would overtake HD as the leading cause of death. Objectives To determine whether changes in national trends had occurred in recent years in mortality rates due to all cardiovascular disease (CVD), HD, stroke, and cancer and to evaluate the gap between mortality rates from HD and cancer. Design, Setting, and Participants The Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research data system was used to determine national trends in age-adjusted mortality rates due to all CVD, HD, stroke, and cancer from January 1, 2000, to December 31, 2011, and January 1, 2011, to December 31, 2014, overall, by sex, and by race/ethnicity. The present study was conducted from December 30, 2105, to January 18, 2016. Main Outcomes and Measures Comparison of annual rates of change and trend in gap between HD and cancer mortality rates. Results The rate of the decline in all CVD, HD, and stroke mortality decelerated substantially after 2011, and the rate of decline for cancer mortality remained relatively stable. Reported as percentage (95% CI), the annual rates of decline for 2000-2011 were 3.79% (3.61% to 3.97%), 3.69% (3.51% to 3.87%), 4.53% (4.34% to 4.72%), and 1.49% (1.37% to 1.60%) for all CVD, HD, stroke, and cancer mortality, respectively; the rates for 2011-2014 were 0.65% (−0.18% to 1.47%), 0.76% (−0.06% to 1.58%), 0.37% (−0.53% to 1.27%), and 1.55% (1.07% to 2.04%), respectively. Deceleration of the decline in all CVD mortality rates occurred in males, females, and all race/ethnicity groups. For example, the annual rates of decline for total CVD mortality for 2000-2011 were 3.69% (3.48% to 3.89%) for males and 3.98% (3.81% to 4.14%) for females; for 2011-2014, the rates were 0.23% (−0.71% to 1.16%) and 1.17% (0.41% to 1.93%), respectively. The gap between HD and cancer mortality persisted. Conclusions and Relevance Deceleration in the decline of all CVD, HD, and stroke mortality rates has occurred since 2011. If this trend continues, strategic goals for lowering the burden of CVD set by the American Heart Association and the Million Hearts Initiative may not be reached.
399 citations
Authors
Showing all 127468 results
Name | H-index | Papers | Citations |
---|---|---|---|
Eric S. Lander | 301 | 826 | 525976 |
George M. Whitesides | 240 | 1739 | 269833 |
Yi Cui | 220 | 1015 | 199725 |
Yi Chen | 217 | 4342 | 293080 |
David Miller | 203 | 2573 | 204840 |
David Baltimore | 203 | 876 | 162955 |
Edward Witten | 202 | 602 | 204199 |
Irving L. Weissman | 201 | 1141 | 172504 |
Hongjie Dai | 197 | 570 | 182579 |
Robert M. Califf | 196 | 1561 | 167961 |
Frank E. Speizer | 193 | 636 | 135891 |
Thomas C. Südhof | 191 | 653 | 118007 |
Gad Getz | 189 | 520 | 247560 |
Mark Hallett | 186 | 1170 | 123741 |
John P. A. Ioannidis | 185 | 1311 | 193612 |